15.48
0.03 (0.16%)
| Penutupan Terdahulu | 15.45 |
| Buka | 15.50 |
| Jumlah Dagangan | 298,770 |
| Purata Dagangan (3B) | 1,478,606 |
| Modal Pasaran | 2,058,966,912 |
| Harga / Pendapatan (P/E TTM) | 6.79 |
| Harga / Pendapatan (P/E Ke hadapan) | 17.64 |
| Harga / Jualan (P/S) | 6.76 |
| Harga / Buku (P/B) | 3.34 |
| Julat 52 Minggu |
| Margin Keuntungan | 16.11% |
| Margin Operasi (TTM) | 37.43% |
| EPS Cair (TTM) | 0.270 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 24.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.25% |
| Nisbah Semasa (MRQ) | 5.93 |
| Aliran Tunai Operasi (OCF TTM) | 64.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 47.49 M |
| Pulangan Atas Aset (ROA TTM) | 5.20% |
| Pulangan Atas Ekuiti (ROE TTM) | 11.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Aurinia Pharmaceuticals Inc | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.33 |
|
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 9.07% |
| % Dimiliki oleh Institusi | 47.53% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tang Capital Management Llc | 31 Mar 2026 | 12,893,814 |
| Nea Management Company, Llc | 31 Mar 2026 | 3,969,834 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |